

Reply to: "AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis"

Trivedi, Palak J; Bruns, Tony; Li, Ka-Kit; Hirschfield, Gideon M

DOI:

[10.1016/j.jhep.2014.08.020](https://doi.org/10.1016/j.jhep.2014.08.020)

License:

Other (please specify with Rights Statement)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Trivedi, PJ, Bruns, T, Li, K-K & Hirschfield, GM 2014, 'Reply to: "AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis"', *Journal of Hepatology*, vol. 61, no. 6, pp. 1445-1446. <https://doi.org/10.1016/j.jhep.2014.08.020>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

NOTICE: this is the author's version of a work that was accepted for publication. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published as Trivedi, P.J., Bruns, T., Li, K-K., Hirschfield, G.M., Reply to: "AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis", *Journal of Hepatology* (2014), doi: <http://dx.doi.org/10.1016/j.jhep.2014.08.020>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Accepted Manuscript

Letter to the Editor

Reply to: “AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis”

Palak J. Trivedi, Tony Bruns, Ka-Kit Li, Gideon M. Hirschfield


PII: S0168-8278(14)00606-0
DOI: <http://dx.doi.org/10.1016/j.jhep.2014.08.020>
Reference: JHEPAT 5299

To appear in: *Journal of Hepatology*

Received Date: 8 August 2014
Accepted Date: 15 August 2014

Please cite this article as: Trivedi, P.J., Bruns, T., Li, K-K., Hirschfield, G.M., Reply to: “AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis”, *Journal of Hepatology* (2014), doi: <http://dx.doi.org/10.1016/j.jhep.2014.08.020>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Reply to: “AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis”

Palak J. Trivedi,^{1,2} Tony Bruns^{1,3,4}, Ka-Kit Li^{1,2} and Gideon M. Hirschfield^{1,2*}

Affiliations

- 1 NIHR Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham, UK
- 2 Liver Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom
- 3 Department of Internal Medicine IV, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany
- 4 Center for Sepsis Control and Care (CSCC), Jena University Hospital, Friedrich Schiller University of Jena, Germany

Palak Trivedi: p.j.trivedi@bham.ac.uk

Tony Bruns: tony.bruns@med.uni-jena.de

Ka-Kit Li: kk15@doctors.org.uk

Gideon Hirschfield: g.hirschfield@bham.ac.uk

*** Address for correspondence:**

Gideon M Hirschfield PhD FRCP

National Institute for Health Research Biomedical Research Unit

University of Birmingham, Birmingham, UK

Keywords: Autoimmune liver disease, ursodeoxycholic acid, outcome prediction, cholestasis, liver transplantation, survival

ACCEPTED MANUSCRIPT

To the Editor:

We read with interest Joshita and colleagues' letter regarding our original article [1]. In taking the time to present their important Japanese data [2], the authors provide further independent validation of AST/platelet ratio (APRI) in risk stratification of patients with primary biliary cirrhosis (PBC). As the authors surmise, whilst the demography of our cohorts was varied it was not representative of all populations globally, and the robustness of any observation – even if simple and low cost as in this case – is in validation more so than discovery.

PBC is not a benign, homogeneous autoimmune liver disease; and although present disease nomenclature needs improvement, the current sole therapy - ursodeoxycholic acid (UDCA) - still leaves a substantial cohort of individuals at risk from life-threatening progressive disease and impaired quality of life. Risk stratification is therefore of value to identify individuals with PBC who will benefit from new treatment and as illustrated herein, APRI at baseline or reapplied 1-year following therapy (APRI-r1) represents an additive tool in identifying those patients at risk of adverse clinical outcome with high accuracy. Joshita et al. also report good correlation between APRI and disease stage; [2] however, it is apparent in both studies that a significant proportion of patients have an APRI >0.54 despite histological evidence of early stage (I-II) disease. Moreover, in our study we were able to show that in those without objective evidence of cirrhosis APRI retains independent predictive value thus supporting APRI/APRI-r1 as a prognostic, clinically meaningful utility beyond application as a surrogate for liver fibrosis.

The ability to reliably predict outcome in patients with PBC is beneficial for patient counselling, timing of diagnostic procedures and therapeutic intervention. In this regard, prospective evaluation of APRI-r1 in terms of additive value to existing UDCA response criteria is of clear importance; particularly given the potential use of surrogate endpoints in development of new treatments in PBC [3–5]. Our observations alongside those of Joshita et al., further substantiate the role stratification could play not just in clinical practice but also in clinical trial design. Hence future therapeutic trials in PBC should consciously consider inclusion criteria beyond classic response criteria, and such stratifiers may include additional tools such as liver elastography and APRI-r1. Finally as is evident by our studies, in the pursuit of optimal management for a rare disease such as PBC, methodologically robust, internationally representative, numerically well-powered cohorts are essential in order to allow investigators to make clear replicated observations about disease nature, course and intervention.

Conflicts of interest

None

References

- [1] Trivedi PJ, Bruns T, Cheung A, Li K-K, Kittler C, Kumagi T, et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. *J Hepatol* 2014;60:1249–58.
- [2] Joshita S, Umemura T, Ota M, Tanaka E. AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis. *J Hepatol* 2014 [Accepted; in Press]
- [3] Lammers WJ, Van Buuren H, Pares A et al. Defining Optimal Laboratory Response Criteria in UDCA Treated Primary Biliary Cirrhosis. Results of an International Multicenter Long-term Follow-up Study. *Hepatology* 2013;58:36A–91A.
- [4] Trivedi PJ, Hirschfield GM. Treatment of autoimmune liver disease: current and future therapeutic options. *Ther Adv Chronic Dis* 2013;4:119–41.
- [5] Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. *Hepatology* 2010;52:349–59.